Freephone Orderline0800 387732
In the past few years there has been major progress in the understanding of the clinical pathophysiology of autoimmune neuropathies. Anti-glycolipid autoantibodies have been implicated as potential pathogenetic agents in a number of peripheral neuropathies. The autoantibodies frequently react with epitopes of the carbohydrate region of cell surface glycoconjugates. Glycoconjugates include glycoproteins (e.g. MAG) or glycolipids (e.g. Gangliosides, SGPG or sulfatides). The value of anti-glycolipid antibody assays for both diagnostic and research purposes (for the study of autoimmune peripheral neuropathies) is increasingly recognised. There is a significant correlation between particular clinical features and the species of anti-glycoconjugate antibodies in the serum. IgG antibodies are associated with acute neuropathies, whereas IgM classes are present in chronic conditions. A variety of peripheral neuropathies can be defined by their anti-glycolipid antibody profile.
The BÜHLMANN GanglioCombi® ELISA product group offers quantitative anti-ganglioside assays in different formats. All assays of this product group have a common standardisation thus allowing inter-assay and inter-laboratory comparability. Each of these assays includes a defined Calibrator - as well as 3 controls of different titers. Results are expressed as %ratio.
Brief product overviews are below but please enquire for further information.
Measurement of anti-C1q autoantibodies in patients with Systemic Lupus Erythematosus (SLE) allows for determination of the risk of the development of active lupus nephritis. This anti-C1q autoantibody ELISA can be used as an inexpensive and technically simple way to exclude the risk of renal flair in the months following the test with a sensitivity of 95%. In the case of active lupus nephritis, consecutive determination of anti-C1q antibodies is a tool to evaluate the efficacy of immunosuppressant treatment.
For the quantitative in vitro determination of human serum IgG and IgM autoantibodies directed against ganglioside M1.
A rapid, technically simple and inexpensive tool to screen IFN-ß treated MS patients for antibodies which may decrease the treatment efficacy. This ELISA was developed to measure virtually all neutralising and non-neutralizing IFN-ß BABs in patient sera.
Based on human Myelin, this anti-MAG ELISA is the most sensitive and specific assay on the market. Not only is it possible to measure even very low anti-MAG antibody titers but also to follow titers in patients under new therapies such as Rituximab.